Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis

被引：0
作者：
Bernhard Neumann
Julia Onken
Nicole König
Henning Stetefeld
Sebastian Luger
Anna-Luisa Luger
Felix Schlachetzki
Ralf Linker
Peter Hau
Elisabeth Bumes
机构：
[1] Regensburg University Hospital,Department of Neurology
[2] Donau-Isar-Klinikum Deggendorf,Department of Neurology
[3] Charité-Universitätsmedizin Berlin,Department of Neurosurgery
[4] corporate member of Freie Universität Berlin,Department of Neurology, Faculty of Medicine and University Hospital Cologne
[5] Humboldt-Universität Zu Berlin,Department of Neurology
[6] University of Cologne,Department of Neurology
[7] RKH Klinikum Ludwigsburg,Dr. Senckenberg Institute of Neurooncology
[8] Goethe University Frankfurt,Frankfurt Cancer Institute (FCI)
[9] University Hospital,University Cancer Center (UCT)
[10] Goethe University Frankfurt,Wilhelm Sander
[11] University Hospital,NeuroOncology Unit
[12] Goethe University Frankfurt,undefined
[13] Goethe University Frankfurt,undefined
[14] University Hospital,undefined
[15] German Cancer Research Center (DKFZ) Heidelberg,undefined
[16] Germany and German Cancer Consortium (DKTK),undefined
[17] Partner Site Frankfurt/Mainz,undefined
[18] Regensburg University Hospital,undefined
来源：
Journal of Neuro-Oncology | 2023年 / 164卷
关键词：
Glioblastoma; Intensive care unit; Invasive mechanical ventilation; Outcome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：249 / 256
页数：7
相关论文
共 128 条
[1]  
Ostrom QT(2014)The epidemiology of glioma in adults: a “state of the science” review Neuro Oncol 16 896-913
[2]  
Bauchet L(2017)Current and future strategies for treatment of glioma Neurosurg Rev 40 1-14
[3]  
Davis FG(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
[4]  
Deltour I(2019)Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial Lancet 393 678-688
[5]  
Fisher JL(2017)Effect of Tumor-Treating Fields Plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a Randomized Clinical Trial JAMA 318 2306-2316
[6]  
Langer CE(2018)F.Y.F. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review J Neurooncol 140 485-496
[7]  
Pekmezci M(2016)Biomarkers related with seizure risk in glioma patients: a systematic review Clin Neurol Neurosurg 151 113-119
[8]  
Schwartzbaum JA(2011)Temozolomide-related infections: review of the literature J buon 16 547-550
[9]  
Turner MC(2016)Neuro-oncological patients admitted in intensive-care unit: predictive factors and functional outcome J Neurooncol 127 111-117
[10]  
Walsh KM(2017)Prognosis of patients with primary malignant brain tumors admitted to the intensive care unit: a two-decade experience J Neurol 264 2303-2312
12345678910